HIMS Plunges 51.2% in 6 Months: Should You Still Hold the Stock or Sell?

Hims & Hers shares have fallen 51.2% over the past six months, even as the company reiterates Q1 2026 revenue guidance of $600M-$625M and full-year 2026 revenue of $2.7B-$2.9B. The article highlights solid top-line growth but weaker profitability, including declining net income, gross margin pressure, and negative free cash flow in Q4 2025. Investors are weighing long-term growth from AI-driven healthcare expansion and the Novo Nordisk partnership against regulatory, execution, and competitive risks.

Analysis

The market is effectively re-rating HIMS from a “scale story” to a “prove-it story.” The key second-order issue is that subscale margin pressure in a regulated consumer-health model tends to persist longer than revenue momentum, because every new category adds compliance, support, and acquisition costs before it adds meaningful operating leverage. That means the stock can stay cheap for longer than bulls expect if each incremental cohort is bought with paid traffic rather than organic trust.

The more important competitive implication is that HIMS’ growth thesis now leans heavily on access to differentiated supply and trusted branded therapies. Any tightening in medication availability, channel economics, or regulatory scrutiny would disproportionately hit a platform whose mix is still working through high-growth, high-spend categories. By contrast, the listed losers in the space are not necessarily the biggest revenue drags; the real beneficiaries are incumbents with distribution, reimbursement relationships, and lower customer-acquisition intensity that can absorb patient demand without needing to defend share with marketing spend.

The consensus may be underestimating how much of the downside is already in the multiple, but overestimating the speed of a margin inflection. If management can show that cohort retention and repeat purchasing are improving faster than acquisition costs, the stock can rerate quickly on a single quarter; if not, the setup resembles a long-duration de-rating with intermittent relief rallies into earnings. The next catalyst window is the May print: a guide that implies even modest operating leverage in the second half could stabilize sentiment, while another cash-flow miss would likely force a further multiple compression over the next 1-2 quarters.

Key Decisions for Investors

• Hold existing HIMS only into earnings with a tight risk budget; if gross margin and operating cash flow do not inflect in Q1/Q2 guidance, trim on strength rather than average down.
• For higher-conviction bearish exposure, buy HIMS put spreads around the May 11 earnings event; the setup favors a volatility expansion if management does not credibly narrow the path to free-cash-flow breakeven.
• Relative-value trade: long NVO / short HIMS for 1-3 months. This isolates the beneficiary of GLP-1 demand and branded supply access against the platform carrying execution and compliance risk.
• If seeking a sector hedge, pair long AMWL vs short HIMS only tactically; AMWL has lower growth quality, but HIMS is the name more vulnerable to a post-earnings multiple reset if spend efficiency weakens.
• Do not initiate a fresh outright long until there is evidence of CAC efficiency improvement or sustained free-cash-flow reversion; without that, upside is more likely to be retracement-driven than trend-driven.